Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant: a Randomized Clinical Trial

• Status: Not yet recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Postreperfusion syndrome during living liver transplants remains a serious concern for transplant anesthesiologists. This syndrome is responsible for decreases in systemic blood pressure, systemic vascular resistance, and cardiac output and can even lead to cardiac arrest. Delayed graft function and primary graft nonfunction are closely related to postreperfusion syndrome (Therefore, attenuating the syndrome during anesthesia is of great importance.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ain Shams University
• Treatments: Mannitol

Criteria

Inclusion Criteria:

• patients with end-stage liver disease who will undergo living donor transplantation.

Exclusion Criteria:

• Patients with a history of portopulmonary hypertension.

• Hepatopulmonary syndrome.

• Cirrhotic cardiomyopathy.

• Hepatorenal syndrome types 1 and 2.